A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2016
At a glance
- Drugs Sonidegib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2014 Planned End Date changed from 1 May 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.